EA201891987A1 - Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она - Google Patents

Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она

Info

Publication number
EA201891987A1
EA201891987A1 EA201891987A EA201891987A EA201891987A1 EA 201891987 A1 EA201891987 A1 EA 201891987A1 EA 201891987 A EA201891987 A EA 201891987A EA 201891987 A EA201891987 A EA 201891987A EA 201891987 A1 EA201891987 A1 EA 201891987A1
Authority
EA
Eurasian Patent Office
Prior art keywords
digidro
methil
pyridazin
phenyl
derivative
Prior art date
Application number
EA201891987A
Other languages
English (en)
Other versions
EA036423B1 (ru
Inventor
Такахиро КАТОХ
Масатоси Иида
Юки Тераути
Казуя Ямагути
Тосиюки Хиросе
Фумихару Йокояма
Хикару Нисимори
Ютака Обути
Хироси Набесима
Емири Такаки
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA201891987A1 publication Critical patent/EA201891987A1/ru
Publication of EA036423B1 publication Critical patent/EA036423B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение предусматривает средство для лечения злокачественной опухоли, содержащее соединение формулы (1)где R-Rпредставляют собой атом водорода, галоген или т.д., Y представляет собой необязательно замещенную алкиленовую группу или т.д.
EA201891987A 2016-03-04 2017-03-02 Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она EA036423B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016042535 2016-03-04
PCT/JP2017/008246 WO2017150654A1 (en) 2016-03-04 2017-03-02 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative

Publications (2)

Publication Number Publication Date
EA201891987A1 true EA201891987A1 (ru) 2019-02-28
EA036423B1 EA036423B1 (ru) 2020-11-10

Family

ID=58347859

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891987A EA036423B1 (ru) 2016-03-04 2017-03-02 Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она

Country Status (28)

Country Link
US (3) US10611731B2 (ru)
EP (1) EP3423440B9 (ru)
JP (1) JP6596595B2 (ru)
KR (1) KR102350772B1 (ru)
CN (1) CN108779076B (ru)
AU (2) AU2017226674B2 (ru)
CA (1) CA3015331A1 (ru)
CY (1) CY1123927T1 (ru)
DK (1) DK3423440T3 (ru)
EA (1) EA036423B1 (ru)
ES (1) ES2862177T3 (ru)
HR (1) HRP20210395T1 (ru)
HU (1) HUE053358T2 (ru)
IL (1) IL261225B (ru)
LT (1) LT3423440T (ru)
MX (1) MX2018010535A (ru)
MY (1) MY196801A (ru)
NZ (1) NZ745688A (ru)
PH (1) PH12018501873A1 (ru)
PL (1) PL3423440T3 (ru)
PT (1) PT3423440T (ru)
RS (1) RS61593B1 (ru)
SA (1) SA518392275B1 (ru)
SG (1) SG11201807146SA (ru)
SI (1) SI3423440T1 (ru)
TW (1) TWI731041B (ru)
WO (1) WO2017150654A1 (ru)
ZA (1) ZA201805791B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7104588B2 (ja) * 2017-09-01 2022-07-21 大塚製薬株式会社 ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤
WO2020157194A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63145272A (ja) * 1986-12-09 1988-06-17 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体
US5100892A (en) 1990-11-13 1992-03-31 Glaxo Inc. Dihydropyridine vasodilator agents
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
CN1136197C (zh) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
JP2008521806A (ja) 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド 心不全を治療するための混合型のＰＤＥ−阻害活性およびβ−アドレナリン作用性アンタゴニスト活性または部分アゴニスト活性を有する化合物
EP2168959A1 (en) 2007-06-19 2010-03-31 Kyorin Pharmaceutical Co., Ltd. Pyridazinone derivative and pde inhibitor containing the same as active ingredient
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
US9890127B2 (en) 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer

Also Published As

Publication number Publication date
SA518392275B1 (ar) 2021-10-11
US20200181092A1 (en) 2020-06-11
KR20180118717A (ko) 2018-10-31
BR112018017324A2 (pt) 2018-12-26
JP6596595B2 (ja) 2019-10-23
NZ745688A (en) 2023-02-24
HRP20210395T1 (hr) 2021-04-16
MX2018010535A (es) 2019-01-10
PT3423440T (pt) 2021-03-11
MY196801A (en) 2023-05-03
CN108779076B (zh) 2022-05-03
US20190023662A1 (en) 2019-01-24
US20210171472A1 (en) 2021-06-10
LT3423440T (lt) 2021-06-10
DK3423440T3 (da) 2021-03-15
EP3423440B9 (en) 2021-07-28
AU2021201135B2 (en) 2022-09-01
EA036423B1 (ru) 2020-11-10
KR102350772B1 (ko) 2022-01-14
ES2862177T3 (es) 2021-10-07
RS61593B1 (sr) 2021-04-29
AU2017226674B2 (en) 2020-12-03
AU2021201135A1 (en) 2021-03-11
US10611731B2 (en) 2020-04-07
WO2017150654A1 (en) 2017-09-08
EP3423440A1 (en) 2019-01-09
TWI731041B (zh) 2021-06-21
CN108779076A (zh) 2018-11-09
JP2019506432A (ja) 2019-03-07
CY1123927T1 (el) 2022-05-27
ZA201805791B (en) 2021-04-28
EP3423440B1 (en) 2021-01-06
IL261225A (en) 2018-10-31
HUE053358T2 (hu) 2021-06-28
PL3423440T3 (pl) 2021-07-26
SI3423440T1 (sl) 2021-07-30
PH12018501873A1 (en) 2019-01-28
AU2017226674A1 (en) 2018-09-13
IL261225B (en) 2021-08-31
TW201736350A (zh) 2017-10-16
CA3015331A1 (en) 2017-09-08
SG11201807146SA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
ZA201906832B (en) Novel psma-binding agents and uses thereof
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201790271A1 (ru) Ингибиторы гликозидазы
MX365590B (es) Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MD3395820T2 (ro) Compuși antitumorali
EA201792287A1 (ru) Способы лечения рака
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
MX2018008507A (es) Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
EA201891987A1 (ru) Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она
EA201891866A1 (ru) N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА
CY1121909T1 (el) Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA201892698A1 (ru) Производные пиразолиламинобензимидазола в качестве ингибиторов jak
MX2021011699A (es) Derivados de quinolina y su uso para el tratamiento del cancer.
EA201991141A1 (ru) Усилители bmp
EA201992557A1 (ru) Противоопухолевые соединения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM